Evidence map›Paper›PMID 32899231›Full record

ReviewInternational journal of molecular sciences2020

The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).

Neelu Batra, Cristabelle De Souza, Jyoti Batra, Alan G Raetz, Ai-Ming Yu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Heme, Heme Oxygenase-1, Statins, and SARS-CoV-2.Antioxidants (Basel, Switzerland) · 2023
    Article
  13. SARS-CoV-2PeerJ · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. The spike protein of SARS-CoV-2 induces heme oxygenase-1: Pathophysiologic implications.Biochimica et biophysica acta. Molecular basis of disease · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Neelu BatraDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.ORCID 0000-0002-8924-2297
Cristabelle De SouzaDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.
Jyoti BatraGladstone Institute, San Francisco, CA 94158, USA.
Alan G RaetzDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.ORCID 0000-0003-2039-3692
Ai-Ming YuDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.ORCID 0000-0003-1441-4012
University of California, Davis · USGladstone Institutes · USUniversity of New Mexico · US

Funding

Novel bioengineered microRNA therapeutics for lung cancerR01CA225958 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aiming Yu · 2019 to 2026
$3.7M
Recombinant microRNAs in xenobiotic dispositionR01GM113888 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2016 to 2019
$1.3M
NCI NIH HHS R01 CA225958NCI NIH HHS R01CA225958NIGMS NIH HHS R01 GM113888NIGMS NIH HHS R01GM113888
6 · The paper itself

Abstract

The coronavirus disease of 2019 (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global pandemic with increasing incidence and mortality rates. Recent evidence based on the cytokine profiles of severe COVID-19 cases suggests an overstimulation of macrophages and monocytes associated with reduced T-cell abundance (lymphopenia) in patients infected with SARS-CoV-2. The SARS-CoV-2 open reading frame 3 a (ORF3a) protein was found to bind to the human HMOX1 protein at a high confidence through high-throughput screening experiments. The HMOX1 pathway can inhibit platelet aggregation, and can have anti-thrombotic and anti-inflammatory properties, amongst others, all of which are critical medical conditions observed in COVID-19 patients. Here, we review the potential of modulating the HMOX1-ORF3a nexus to regulate the innate immune response for therapeutic benefits in COVID-19 patients. We also review other potential treatment strategies and suggest novel synthetic and natural compounds that may have the potential for future development in clinic.

Indexed as

AnimalsAntiviral AgentsCoronavirus InfectionsCOVID-19Heme Oxygenase-1HumansPandemicsPneumonia, ViralProtein BindingViral Regulatory and Accessory ProteinsViroporin ProteinsAntiviral AgentsHeme Oxygenase-1HMOX1 protein, humanORF3a protein, SARS-CoV-2Viral Regulatory and Accessory ProteinsViroporin Proteinsanti-viral therapyHMOX1HMOX1-ORF3anatural compoundsORF3aSARS-CoV-2

Identifiers

PMID32899231
PMCPMC7503392
OpenAlexW3081992458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.